NLRP3 and amyloidosis: NLRP3 selective inhibitors (e.g. MCC950, OLT1177) that have shown effective for reversing AD pathology in amyloid mouse models [8, 11], might not be enough to suppress IL-1β levels and the detrimental effects of IL-1β in human AD.